PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors

PIOS（Patras免疫治疗评分）与接受抗程序性细胞死亡蛋白-1（PD-1）抑制剂治疗的晚期非小细胞肺癌（NSCLC）患者的最佳总体反应、无进展生存期和免疫治疗后总生存期相关。